Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

Acta Neuropathologica

Volumn 120, Issue 6, 2010, Pages 719-729

  Metellus, Philippe ^a,b,c   Coulibaly, Bema ^a   Colin, Carole ^b,c   De Paula, Andre Maues ^a   Vasiljevic, Alexandre ^a   Taieb, David ^a   Barlier, Anne ^a,c,d   Boisselier, Blandine ^d,e,f   Mokhtari, Karima ^d,e,f   Wang, Xiao Wei ^d,e,f   Loundou, Anderson ^a   Chapon, Frederique ^a   Pineau, Sandrine ^a   Ouafik, L'Houcine ^b,c   Chinot, Olivier ^a,b,c   Figarella Branger, Dominique ^a,b,c  

^a TIMONE HOSPITAL   (France)

^b University of the Mediterranean Aix Marseille II   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CNRS   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f INSERM   (France)

Author keywords

IDH2; Isocitrate dehydrogenase 1(IDH1); LOH 1p19q mutation; Low grade glioma; P53; Prognosis

Indexed keywords

ISOCITRATE DEHYDROGENASE; PROTEIN P53;

ADULT; AGED; AGING; ARTICLE; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INFILTRATION; CANCER RADIOTHERAPY; CHROMOSOME 1P; CLINICAL ARTICLE; CLINICAL FEATURE; CODON; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GLIOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INSULA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

EID: 78651067051     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-010-0777-8     Document Type: Article

References (53)

1. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M (1993) p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 55:982-987
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602
3. Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D (2009) Adult supratentorial low-grade glioma: Long-term experience at a single institution. Int J Radiat Oncol Biol Phys 75:1401-1407
4. Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7-11
5. Bouvier C, Roll P, Quilichini B et al (2004) Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: Usefulness for stereotactic biopsies. J Neurooncol 68:141-149
6. Brown R, Zlatescu M, Sijben A et al (2008) The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14:2357-2362
7. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599-601
8. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quinones-Hinojosa A (2010) Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 112:10-17
9. Chaichana KL, McGirt MJ, Niranjan A, Olivi A, Burger PC, Quinones-Hinojosa A (2009) Prognostic significance of contrastenhancing low-grade gliomas in adults and a review of the literature. Neurol Res 31:931-939
10. Chang EF, Clark A, Jensen RL et al (2009) Multiinstitutional validation of the University of California at San Francisco Low- Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg 111:203-210
11. Chang EF, Smith JS, Chang SM et al (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 109:817-824
12. Coulibaly B, Nanni I, Quilichini B et al (2010) Epidermal growth factor receptor in glioblastomas: Correlation between gene copy number and protein expression. Hum Pathol 41:815-823
13. Dhermain F, Saliou G, Parker F et al (2010) Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas. J Neurooncol 97:81-88
14. Dubbink HJ, Taal W, van Marion R et al (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73:1792-1795
15. Fallon KB, Palmer CA, Roth KA et al (2004) Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314-322
16. Felsberg J, Erkwoh A, Sabel MC et al (2004) Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14:121-130
17. Figarella-Branger D, Colin C, Coulibaly B et al (2008) Histological and molecular classification of gliomas. Rev Neurol (Paris) 164:505-515
18. Goze C, Rigau V, Gibert L, Maudelonde T, Duffau H (2009) Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: A marker of worse prognosis? J Neurooncol 91:1-5
19. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1, 010 diffuse gliomas. Acta Neuropathol 118:469-474
20. Huang L, Jiang T, Yuan F, Li GL, Liu EZ, Wang ZC (2008) Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors. Clin Neurol Neurosurg 110:1020-1024
21. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347
22. Iwamoto FM, Nicolardi L, Demopoulos A et al (2008) Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol 88:293-298
23. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: Correlation with MRI features. Brain 129:1884-1891
24. Kapoor GS, Gocke TA, Chawla S et al (2009) Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 92:373-386
25. Koga H, Zhang S, Kumanishi T et al (1994) Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87:225-232
26. Korshunov A, Golanov A, Sycheva R (2002) Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neurooncol 58:237-253 (Pubitemid 34830635)
27. Labussiere M, Idbaih A, Wang XW et al (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886-1890
28. Laigle-Donadey F, Martin-Duverneuil N, Lejeune J et al (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63:2360-2362
29. Law M, Young RJ, Babb JS et al (2008) Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490-498
30. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109
31. Louis DN, von Deimling A, Chung RY et al (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52:31-38
32. Mariani L, Deiana G, Vassella E et al (2006) Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 24:4758-4763
33. McGirt MJ, Chaichana KL, Attenello FJ et al (2008) Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 63:700-707 (author reply 707-708)
34. Megyesi JF, Kachur E, Lee DH et al (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303-4306
35. Mueller W, Hartmann C, Hoffmann A et al (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313-319
36. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3:229-235
37. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479-489
38. Okamoto Y, Di Patre PL, Burkhard C et al (2004) Populationbased study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49-56
39. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
40. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117-1124
41. Pignatti F, van den Bent M, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084
42. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: State of the art. Acta Neuropathol 120(5):567-584
43. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
44. Shaw EG, Berkey B, Coons SW et al (2008) Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: Results of a prospective clinical trial. J Neurosurg 109:835-841
45. Smith JS, Chang EF, Lamborn KR et al (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338-1345
46. Smith JS, Tachibana I, Lee HK et al (2000) Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 29:16-25
47. Stander M, Peraud A, Leroch B, Kreth FW (2004) Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: A long-term analysis. Cancer 101:1028-1035
48. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D (2003) Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: Relationship to outcome and chemosensitivity. J Neurooncol 64:271-278
49. van den Bent MJ, Dubbink HJ, Marie Y et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16(5):1597-1604
50. van den Bent MJ, Looijenga LH, Langenberg K et al (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284
51. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153
52. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
53. Zlatescu MC, TehraniYazdi A, Sasaki H et al (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713-6715